• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人类呼吸道合胞病毒生物学：免疫反应及抗病毒机制的当前观点

Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus.

作者信息

Girma Abayeneh

机构信息

Department of Biology, College of Natural and Computational Sciences, Mekdela Amba University, P.O. Box 32, Tulu Awuliya, Ethiopia.

出版信息

Virus Res. 2024 Dec;350:199483. doi: 10.1016/j.virusres.2024.199483. Epub 2024 Oct 18.

DOI:10.1016/j.virusres.2024.199483
PMID:39396572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11513633/
Abstract

Human respiratory syncytial virus (hRSV) remains a leading cause of morbidity and mortality in infants, young children, and older adults. hRSV infection's limited treatment and vaccine options significantly increase bronchiolitis' morbidity rates. The severity and outcome of viral infection hinge on the innate immune response. Developing vaccines and identifying therapeutic interventions suitable for young children, older adults, and pregnant women relies on comprehending the molecular mechanisms of viral PAMP recognition, genetic factors of the inflammatory response, and antiviral defense. This review covers fundamental elements of hRSV biology, diagnosis, pathogenesis, and the immune response, highlighting prospective options for vaccine development.

摘要

人类呼吸道合胞病毒（hRSV）仍然是婴幼儿和老年人发病和死亡的主要原因。hRSV感染的治疗和疫苗选择有限，显著增加了细支气管炎的发病率。病毒感染的严重程度和结果取决于先天免疫反应。开发适合幼儿、老年人和孕妇的疫苗并确定治疗干预措施，依赖于理解病毒病原体相关分子模式识别的分子机制、炎症反应的遗传因素以及抗病毒防御。本综述涵盖了hRSV生物学、诊断、发病机制和免疫反应的基本要素，重点介绍了疫苗开发的潜在选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b9/11513633/1a7a6c4e1c7e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b9/11513633/d5c35e017cd6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b9/11513633/1a7a6c4e1c7e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b9/11513633/d5c35e017cd6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b9/11513633/1a7a6c4e1c7e/gr2.jpg

相似文献

1
Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus.人类呼吸道合胞病毒生物学：免疫反应及抗病毒机制的当前观点
Virus Res. 2024 Dec;350:199483. doi: 10.1016/j.virusres.2024.199483. Epub 2024 Oct 18.
2
Human Respiratory Syncytial Virus: Role of Innate Immunity in Clearance and Disease Progression.人呼吸道合胞病毒：固有免疫在清除病毒及疾病进展中的作用
Viral Immunol. 2016 Jan-Feb;29(1):11-26. doi: 10.1089/vim.2015.0098. Epub 2015 Dec 17.
3
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.呼吸道合胞病毒所致肺炎的免疫学特征——对疫苗设计的启示
Int J Mol Sci. 2017 Mar 4;18(3):556. doi: 10.3390/ijms18030556.
4
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.单剂量低剂量的cGMP重组卡介苗可引发针对人类呼吸道合胞病毒感染的保护性T细胞免疫，并预防小鼠的肺部病变。
Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Epub 2017 Jan 5.
5
Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.高龄人群针对人呼吸道合胞病毒感染的疫苗接种免疫反应受损。
J Virol. 2014 Sep 1;88(17):9744-50. doi: 10.1128/JVI.01101-14. Epub 2014 Jun 11.
6
A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.一种安全有效的 BCG 载体疫苗，用于预防由人类呼吸道合胞病毒引起的疾病。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2092-2097. doi: 10.1080/21645515.2017.1334026. Epub 2017 Jun 9.
7
New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.有助于开发有效疫苗和疗法以减少人呼吸道合胞病毒所致病理的新见解。
Int J Mol Sci. 2017 Aug 11;18(8):1753. doi: 10.3390/ijms18081753.
8
Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.新型疫苗方案可引发非人类灵长类动物强烈的气道免疫应答和呼吸道合胞病毒控制。
J Virol. 2014 Apr;88(8):3997-4007. doi: 10.1128/JVI.02736-13. Epub 2014 Jan 22.
9
Bovine model of respiratory syncytial virus infection.牛呼吸道合胞病毒感染模型。
Curr Top Microbiol Immunol. 2013;372:327-45. doi: 10.1007/978-3-642-38919-1_16.
10
CD8+ T cell immunity against human respiratory syncytial virus.针对人类呼吸道合胞病毒的CD8 + T细胞免疫
Vaccine. 2014 Oct 21;32(46):6130-7. doi: 10.1016/j.vaccine.2014.08.063. Epub 2014 Sep 16.

引用本文的文献

1
Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis.初呼吸之外：通过母体免疫和婴儿免疫预防实现呼吸道合胞病毒的全面防控
Asian Biomed (Res Rev News). 2025 Jul 28;19(3):116-130. doi: 10.2478/abm-2025-0015. eCollection 2025 Jun.

本文引用的文献

1
A Scoring System to Predict Severe Acute Lower Respiratory Infection in Children Caused by Respiratory Syncytial Virus.一种预测呼吸道合胞病毒引起的儿童严重急性下呼吸道感染的评分系统。
Microorganisms. 2024 Jul 12;12(7):1411. doi: 10.3390/microorganisms12071411.
2
Respiratory Syncytial Virus-Associated Deaths among Children under Five before and during the COVID-19 Pandemic in Bangladesh.孟加拉国 COVID-19 大流行前后五岁以下儿童因呼吸道合胞病毒死亡的情况。
Viruses. 2024 Jan 12;16(1):111. doi: 10.3390/v16010111.
3
Current state and challenges in respiratory syncytial virus drug discovery and development.
呼吸道合胞病毒药物研发的现状与挑战。
Antiviral Res. 2024 Jan;221:105791. doi: 10.1016/j.antiviral.2023.105791. Epub 2023 Dec 29.
4
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《妊娠期使用辉瑞呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病：免疫实践咨询委员会建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
5
FDA approves long-acting RSV antibody.美国食品药品监督管理局批准长效呼吸道合胞病毒抗体。
Nat Rev Drug Discov. 2023 Sep;22(9):687. doi: 10.1038/d41573-023-00130-9.
6
Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years.欧盟呼吸道合胞病毒负担：5岁以下儿童呼吸道合胞病毒相关住院病例数估计
J Infect Dis. 2023 Nov 28;228(11):1528-1538. doi: 10.1093/infdis/jiad188.
7
Structures and Mechanisms of Nonsegmented, Negative-Strand RNA Virus Polymerases.非节段负链RNA病毒聚合酶的结构与机制
Annu Rev Virol. 2023 Sep 29;10(1):199-215. doi: 10.1146/annurev-virology-111821-102603. Epub 2023 May 3.
8
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.一种二价呼吸道合胞病毒预融合F疫苗在老年人中的疗效和安全性
N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
9
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.老年人呼吸道合胞病毒预融合F蛋白疫苗
N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
10
Development of mRNA vaccines against respiratory syncytial virus (RSV).mRNA 疫苗防治呼吸道合胞病毒（RSV）的研发。
Cytokine Growth Factor Rev. 2022 Dec;68:37-53. doi: 10.1016/j.cytogfr.2022.10.001. Epub 2022 Oct 13.